All In Biotech

Drug Trial Radar · NCT06773910

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

An Open-label, Randomized Study of BMS-986489 (Atigotatug + Nivolumab Fixed-dose Combination) vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Mar 11, 2025

Primary completion

May 2032

Study completion Sep 2032

Sponsor

Lead sponsor
SCRI Development Innovations, LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bristol-Myers Squibb
First posted
Jan 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489

Conditions

  • Limited Stage Small Cell Lung Cancer

Interventions

  • BMS-986489Drug

    BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.

  • DurvalumabDrug

    Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of BMS-986489 vs durvalumab by Overall Survival (OS).Time frame: From date of randomization up to 5 years. Every 8 weeks for participants who stopped treatment before disease progression and before completing 6 months of treatment and every 12 weeks for participants who stopped treatment before disease progression and

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Daphne, Alabama

  • Sansum Clinic

    Santa Barbara, California

  • Florida Cancer Specialists - South

    Fort Myers, Florida

  • University of Miami - Sylvester Cancer Center

    Miami, Florida

  • Ocala Oncology Center

    Ocala, Florida

  • Florida Cancer Specialists - North

    Orange City, Florida

  • Cancer Care Centers of Brevard

    Palm Bay, Florida

  • Florida Cancer Specialists - East

    West Palm Beach, Florida

  • Piedmont Healthcare - Atlanta

    Atlanta, Georgia

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • Illinois Cancer Care

    Peoria, Illinois

  • Indiana University Simon Cancer Center

    Indianapolis, Indiana

  • Baptist Health - Corbin

    Corbin, Kentucky

  • Baptist Health - Lexington

    Lexington, Kentucky

  • Baptist Health - Louisville

    Louisville, Kentucky

  • Minnesota Oncology Hematology

    Maple Grove, Minnesota

  • Missouri Cancer Associates

    Columbia, Missouri

  • White Plains Hospital Physician Associates

    White Plains, New York

  • Carolina Cancer Research Center

    Wilson, North Carolina

  • Oncology Hematology Care

    Cincinnati, Ohio

  • The Ohio State University - Arthur James Cancer Hospital & Solove Research Institute

    Columbus, Ohio

  • Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center

    Columbus, Ohio

  • Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center)

    Eugene, Oregon

  • Tennessee Cancer Specialists

    Knoxville, Tennessee

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Texas Oncology - West Texas

    Amarillo, Texas

  • Texas Oncology- Austin

    Austin, Texas

  • Texas Oncology - Gulf Coast

    Beaumont, Texas

  • Texas Oncology - DFW

    Dallas, Texas

  • Texas Oncology - Northeast Texas

    Denison, Texas

  • Texas Oncology - San Antonio

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA)

    Salem, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.